SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong7/28/2017 9:41:02 PM
   of 7424
 
FDA panel says data supports safety of Dynavax hepatitis B vaccine
  • Dynavax Technologies (NASDAQ: DVAX) +83.7% AH after saying that an FDA advisory panel voted 12-1 that available data supports the safety of its experimental hepatitis B vaccine when administered to adults.
  • DVAX says a prior panel voted 13-1 that data from Phase 3 clinical trials supports the effectiveness of the Heplisav-B vaccine.
  • If the FDA approves the vaccine, peak sales could reach $650M/year, says William Blair analyst Katherine Xu, adding that Heplisav could become the standard of care since it has an easier dosing schedule than GlaxoSmithKline's Engerix-B.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News